Internal Medicine, Medical Oncology · McAllen, TX
NPI
1760421101
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1901 S 2nd St
McAllen, TX, 78503
Phone (956) 687-5150
Groups this clinician bills Medicare through
Medicare paid, 2024
$618K
51,727 services
Medicare patients, 2024
352
Average age 73
Drug cost, 2024
$4.6M
1,270 prescriptions
Company payments, 2025
$2,323
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Guillermo Lazo-Diaz was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 7,650 times for 11 patients. In total Guillermo Lazo-Diaz billed 51,727 services in 129 codes, and Medicare paid $618K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-12-11.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 7,650 | 11 | $0.25 | $1,919 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,785 | 22 | $0.10 | $173 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,400 | 11 | $16.27 | $23K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,040 | 16 | $5.85 | $6,082 |
| 36415 Venipuncture Blood Collection | Office | 710 | 180 | $8.65 | $6,142 |
| 85025 Blood Count | Office | 689 | 184 | $7.59 | $5,230 |
| 80053 Clinical Chemistry | Office | 661 | 184 | $10.32 | $6,824 |
| 83615 Clinical Chemistry | Office | 604 | 175 | $5.91 | $3,571 |
| 99214 Office E&M - Established | Office | 373 | 158 | $89.11 | $33K |
| 82728 Clinical Chemistry | Office | 203 | 96 | $13.36 | $2,712 |
| 83540 Clinical Chemistry | Office | 203 | 96 | $6.34 | $1,287 |
| 83550 Clinical Chemistry | Office | 203 | 96 | $8.57 | $1,740 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 165 | 103 | $11.49 | $1,896 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 135 | 14 | $0.09 | $12.1 |
| 96372 Injection Administration | Office | 103 | 41 | $10.13 | $1,044 |
By year: 2022 $681K for 46,388 services; 2023 $477K for 41,711 services; 2024 $618K for 51,727 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 710 | 180 | $8.65 | $6,142 |
| 85025 Blood Count | 689 | 184 | $7.59 | $5,230 |
| 80053 Clinical Chemistry | 661 | 184 | $10.32 | $6,824 |
| 83615 Clinical Chemistry | 604 | 175 | $5.91 | $3,571 |
| 83550 Clinical Chemistry | 203 | 96 | $8.57 | $1,740 |
| 83540 Clinical Chemistry | 203 | 96 | $6.34 | $1,287 |
| 82728 Clinical Chemistry | 203 | 96 | $13.36 | $2,712 |
| 85055 Blood Count | 55 | 23 | $35.03 | $1,927 |
| 85046 Blood Count | 16 | 16 | $5.46 | $87.36 |
| 85610 Clinical Chemistry | 15 | 11 | $4.20 | $63 |
Medicare prescription drug claims, 2024
In 2024, the drug Guillermo Lazo-Diaz prescribed most often to Medicare patients was Anastrozole, with 211 prescriptions and refills. In total Guillermo Lazo-Diaz wrote 1,270 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 211 | 486 | 53 | $2,955 |
| Revlimid Lenalidomide | 68 | 70 | 16 | $1.1M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 67 | 67 | 23 | $2,341 |
| Hydroxyurea Generic | 66 | 136 | 16 | $1,369 |
| Acyclovir Generic | 61 | 62 | 11 | $436 |
| Dexamethasone Generic | 55 | 62 | 20 | $328 |
| Prednisone Generic | 48 | 48 | 13 | $235 |
| Tamoxifen Citrate Generic | 44 | 90 | 14 | $1,130 |
| Verzenio Abemaciclib | 31 | 31 | Under 11 | $298K |
| Eliquis Apixaban | 30 | 43 | Under 11 | $24K |
| Letrozole Generic | 30 | 77 | 12 | $783 |
| Imatinib Mesylate Generic | 29 | 37 | Under 11 | $73K |
| Levothyroxine Sodium Generic | 28 | 65 | 11 | $196 |
| Abiraterone Acetate Generic | 24 | 24 | Under 11 | $60K |
| Levofloxacin Generic | 21 | 22 | 17 | $109 |
Brand drugs: 325 claims; generic drugs: 945 claims; opioid claims: 105.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Guillermo Lazo-Diaz $2,323 ($2,323 in general payments such as food, travel and fees) from 24 companies. The largest payer was Incyte Corporation with $860.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 1 | $860 |
| Abbvie Inc. ABBV | 4 | $198 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $153 |
| Boston Scientific Corporation BSX | 1 | $138 |
| Exelixis Inc. EXEL | 2 | $124 |
| Celgene Corporation BMY | 5 | $119 |
| Gilead Sciences, Inc. GILD | 5 | $103 |
| Pfizer Inc. PFE | 3 | $75.82 |
| Genentech USA, Inc. ROG.SW | 3 | $70.69 |
| Merck Sharp & Dohme LLC MRK | 3 | $59.87 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.